AstraZeneca gets novel anti-infective for Korean firm, AC Immune adds to Alzheimer's portfolio with Russian drug

Anglo-Swedish drug major AstraZeneca has entered into a research collaboration with South Korea-based CrystalGenomics to discover and develop a novel anti-infective for use as a potential antibacterial agent.

Under the terms of this agreement, CrystalGenomics will receive research funding from AstraZeneca for two years. It will also be eligible to receive future milestones and royalty payments associated with development and commercialization of a drug candidate. Further financial terms were not disclosed.

This is the first such infection research collaboration AstraZeneca has entered into with a Korean-based company and further demonstrates its commitment to Asia, the London-based firm noted.